The project is of interest but potentially underpowered for its main analysis. Nevertheless, it will provide valuable pilot data to inform future research.

It would be interesting to include an interaction term in their logistic model, to determine whether the presence of the immunomodulator modifies the effect of trough infliximab concentration on remission.